Nanoparticles are tiny objects, available only as intravenous formulations, that help medicines get to difficult-to-reach cells and tissue. They can also help protect molecules and control the targeted release...
During lead generation, many molecules are tested for target interaction. These may then need to be altered, or optimised, in order to improve their effect on the target.
Non-clinical toxicity studies investigate the safety profile of a medicine. Candidate compounds must undergo many different toxicity studies before they are first administered in clinical trials or receive marketing...
There are several forms of data collection in clinical trials, including electronic methods and Patient Reported Outcomes (PROs). All forms of data collection must adhere to Good Clinical Practice...
After they are published, clinical study results should be critically reviewed and assessed for such things as reliability, bias, significance, and fit with existing literature.
HTA is a multidisciplinary process that examines the information about medical, cost-effectiveness, social, political, legal and ethical considerations of the application of a health technology – usually a medicine,...
‘Within-trial decisions’ are decisions made once a clinical trial has already begun, for instance if an unexpected problem comes to light. This article looks at two specific kinds of...
A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led...
Patient engagement in medicines development: Recommendations on how to find the right match for the right patient engagement activity. Background/Rationale for the document During the analysis of existing practices...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
